Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad.

40
Zudus

Last Updated on June 27, 2021 by The Health Master

Zydus Cadila has received tentative approval from the USFDA to market Pemetrexed for Injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials (US RLD: Alimta), the company said in a statement.

The statement added that Pemetrexed is used to treat certain types of cancers such as lung cancer and mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

“The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad.

The group now has 319 approvals and has, so far, filed over 400 ANDAs since the commencement of the filing process in FY 2003-04,” notified the statement.

Cipla gets USFDA nod for Inhalation product

Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

Alkem gets two observations from USFDA for USA plant

Lupin gets USFDA nod for treatment of Kidney patient

Aleor gets USFDA nod for Testosterone Topical Solution

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol

Copyright – An article (Part-1)

DCGI allows to conduct phase-III clinical trials on C-19 drug

Mankind, BDR Pharma to distribute Baricitinib in India

Dr. Reddy’s Labs launches Icosapent Ethyl Capsules

IPC to sensitize stakeholders on manufacturing of Quality Drugs

Mankind launches drug to treat Diabetes, Heart failure

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner